Any known additional malignancy that is progressing or required active treatment in the last  years
Has an active infection requiring systemic therapy or uncontrolled infection. Has a known additional malignancy that is progressing or requires active treatment. Has an underlying medical condition that would preclude study participation.
Has a known additional malignancy that is progressing or requires active treatment within the past  years.
Known additional malignancy that is progressing or requires active treatment within  years of start of study drug.
Has a known additional malignancy that is progressing or requires active treatment
Has had known additional malignancy that is progressing or requires active treatment, or history of other malignancy within  years of study entry.
Known additional malignancy that is progressing or requires active treatment
Known additional malignancy that requires active systemic treatment
Has a known additional malignancy that is progressing or requires active treatment
Has a known additional malignancy that is progressing or requires active treatment
Have a known additional malignancy that is progressing or required active treatment within the past  year.
Has a known additional malignancy that is progressing or requires active treatment; patients with a stage I-III cancer that has been cured over two years ago are not excluded in the study
Has known active additional malignancy that is undergoing active treatment
Has a known additional malignancy that is progressing or requires active treatment
Has a known additional malignancy that is progressing or requires active treatment
Subject has a known additional malignancy that is progressing or requires active treatment
Known additional malignancy that is progressing or requires active treatment.
Has a known additional malignancy that is progressing or requires active treatment.
Has a known additional malignancy that is progressing or has required active treatment within the past  years
Has a known additional malignancy that is progressing or requires active treatment
Known additional malignancy that is progressing or requires active treatment or that may interfere with interpretation of response evaluation, in the judgment of the investigator
Known additional malignancy that is progressing or has required active treatment within the past  years.
Has a known additional malignancy that is progressing or requires active treatment within the past  years.
Known additional malignancy that required treatment or progressed in last  years
Known additional malignancy that is progressing or requires active treatment except superficial malignancies of the skin and in situ cervical cancer
Known additional malignancy that is progressing or has required active treatment within the past  years.
Known additional malignancy that is progressing or has required active treatment within the past  years.
Known additional malignancy that has progressed or has required active treatment in the last  years.
Known additional malignancy that is progressing or requires active treatment
Known additional malignancy that is progressing or requires active treatment
Has a known additional malignancy that is progressing or requires active treatment.
Requires additional therapy, as determined by the investigator.
